{"id":789250,"date":"2026-02-06T20:53:01","date_gmt":"2026-02-06T20:53:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=789250"},"modified":"2026-02-06T20:53:01","modified_gmt":"2026-02-06T20:53:01","slug":"eleve-behavioral-health-increases-treatment-capacity-to-meet-rising-demand-for-addiction-and-mental-health-care","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/eleve-behavioral-health-increases-treatment-capacity-to-meet-rising-demand-for-addiction-and-mental-health-care_789250.html","title":{"rendered":"Eleve Behavioral Health Increases Treatment Capacity to Meet Rising Demand for Addiction and Mental Health Care"},"content":{"rendered":"

Voorhees Township, NJ – February 6, 2026 –<\/strong> Eleve Behavioral Health<\/a>, a leading provider of outpatient addiction, mental health, and dual-diagnosis treatment in New Jersey, announced today that it has increased its clinical capacity to meet the growing number of individuals seeking professional behavioral healthcare.<\/p>\n

Across the region, more people are reaching out for help with substance use, anxiety, depression, trauma, and co-occurring disorders. Eleve’s enhanced staffing, expanded clinical schedules, and optimized program structure now allow the organization to serve more clients while maintaining its personalized, evidence-based approach to care.<\/p>\n

“We’ve seen a significant increase in individuals and families looking for high-quality outpatient treatment,” said a spokesperson for Eleve Behavioral Health. “By increasing our capacity, we are able to reduce wait times and provide more timely access to life-saving care — without compromising the individualized attention our clients deserve.”<\/p>\n

Eleve Behavioral Health provides a full continuum of outpatient services, including Partial Hospitalization (PHP) and Intensive Outpatient Programs (IOP). Treatment is built around trauma-informed therapy, psychiatric care, medication-assisted treatment when appropriate, and structured recovery planning to support long-term stability.<\/p>\n

The increased capacity also strengthens Eleve’s ability to treat individuals with co-occurring mental health and substance use disorders, an area of growing need as anxiety, depression, and trauma continue to drive addiction rates nationwide.<\/p>\n

“Our mission is to meet people where they are and give them the tools to build a sustainable recovery,” the spokesperson added. “This increased capacity allows us to support more people at the exact moment they’re ready to seek help.”<\/p>\n

Eleve’s outpatient model allows clients to receive high-level clinical care while continuing to live at home and maintain work, school, and family responsibilities — a critical advantage for those who need flexibility without sacrificing quality of treatment.<\/p>\n

About Eleve Behavioral Health<\/strong><\/p>\n

Eleve Behavioral Health provides personalized outpatient treatment for addiction, mental health, and dual-diagnosis conditions in Voorhees Township, New Jersey. Eleve combines evidence-based therapy, psychiatric care, trauma-informed treatment, and recovery support to help individuals achieve lasting wellness and stability.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Eleve Behavioral Health<\/a>
Contact Person:<\/strong> PR Specialist
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> (833) 348-9389
Address:<\/strong>1307 White Horse Rd, Suite A103
City:<\/strong> Voorhees Township
State:<\/strong> NJ 08043
Country:<\/strong> United States
Website:<\/strong> https:\/\/elevebh.com\/<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Voorhees Township, NJ – February 6, 2026 – Eleve Behavioral Health, a leading provider of outpatient addiction, mental health, and dual-diagnosis treatment in New Jersey, announced today that it has increased its clinical capacity to meet the growing number of individuals … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,412,406,423,404],"tags":[],"class_list":["post-789250","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-News-Current-Affairs","category-Pharmaceuticals-Biotech","category-Professional-Services","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/789250","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=789250"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/789250\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=789250"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=789250"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=789250"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}